Furthermore, the efficacy of human NEXN gene replacement therapy in treating G645del mice, which have similar clinical pathological and genetic features to human DCM patients, provided a promising intervention for further clinical therapeutics. This evidence concerns the gene NEXN and familial dilated cardiomyopathy.